B-Cell Lymphomas, Version 5.2021 Featured Updates to the NCCN Guidelines

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody- drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

Automated summary

In the past decade, advancements in understanding the molecular pathogenesis of B-cell non-Hodgkin lymphomas have led to the development of novel targeted therapies, including small molecule inhibitors of select kinases, antibody-drug conjugates, and small molecules targeting various proteins. These therapies, such as anti-CD19 CAR T-cell therapy, have been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma, and also show promise for follicular lymphoma and mantle cell lymphoma. These developments are highlighted in the NCCN Guidelines for B-Cell Lymphomas.